Imprimis Pharmaceuticals Stock News

Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sho

Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "

As December 2022 comes to a close, we observe six new preferred stock / exchange-traded-debt (ETD) offerings during the month, offering annual yields ranging from 6.75% to 11.875%. Here is a compariso

Harrow Health is a founder-led eyecare company, the CEO holds 10% of the shares. It is moving up the value chain with a focus on branded products such as a recent (second) deal with Novartis.

Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic

Sienna Harrow Health, Inc. (NASDAQ:HROW ) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today

Harrow Health, Inc. (NASDAQ:HROW ) Q2 2022 Earnings Conference Call August 9, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Exec

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophth

These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared f

Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43% YOY. Harrow entered a

Harrow Health's (NASDAQ:HROW ) Q1 2022 Earnings Conference Call May 5, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive O

Harrow Health press release (HROW): Q4 GAAP EPS of -$0.27 misses by $0.23.Revenue of $20.2M (+38.4% Y/Y) beats by $0.84M.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2021. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “The fourth quarter of 2021 represents our sixth consecutive quarter of record performance in many key financial and operational metrics, providing a soli